지니너스

389030KOSDAQSector: Pharma & Biotech

₩2,040▼ 0.73%Market cap ₩80.4BAs of Jul 21, 2026 close · updated once daily

Grade D28 ptsTop 89% of 2,523 stocks

Financial strength

12.4

Growth momentum

70.0

Price attractiveness

15.7

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

Financial strength

12.4

How much debt does it carry relative to equity?

Debt-to-equity ratio

332.3%

✗ Below median · Top 95.3% in sector

Sector median 51.5%

Can it cover what's due within a year?

Current ratio

76.8%

✗ Below median · Top 83.9% in sector

Sector median 191.3%

How much of revenue becomes profit?

Operating margin

-111.3%

✗ Below median · Top 75.5% in sector

Sector median -2.3%

How much did it earn on its own capital?

ROE (return on equity)

-190.9%

✗ Below median · Top 95.7% in sector

Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

Growth momentum

70.0

How much did revenue grow in a year?

Revenue growth (YoY)

62.4%

✓ Above median · Top 11.2% in sector

Sector median 6.4%

Did core profits grow in a year?

Operating income change (YoY)

4.8%

✓ Above median · Top 48.9% in sector

Sector median 3.6%

Source filing: annual report (consolidated) — view original ↗

Price attractiveness

15.7

Is the price expensive relative to earnings?

P/E (price-to-earnings)

Loss-making (P/E not computable)

✗ Below median · Top 83.5% in sector

Sector median P/E of profitable peers 14.4x · 57% loss-making

Is the price expensive relative to book value?

P/B (price-to-book)

8.83x

✗ Below median · Top 85.2% in sector

Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15